I. Tikkanen

发表

4B.01: CONTRASTING INFLUENCES OF RENAL FUNCTION ON BLOOD PRESSURE AND HBA1C REDUCTIONS WITH EMPAGLIFLOZIN IN PATIENTS WITH TYPE 2 DIABETES AND HYPERTENSION

M. Cooper, U. Broedl, H. Woerle, 2015, Journal of hypertension.

Abstract 16474: BP Reduction With the Sodium Glucose Co-Transporter 2 Inhibitor Empagliflozin in Type 2 Diabetes is Similar in Treatment Naïve as in Those on One or ≥ 2 Antihypertensive Agents - Further Insights From a Dedicated 24h ABPM Study

C. Cannon, U. Broedl, H. Woerle, 2014 .